伏立康唑对某些临床重要真菌的体外评价。
In vitro evaluation of voriconazole against some clinically important fungi.
作者信息
McGinnis M R, Pasarell L, Sutton D A, Fothergill A W, Cooper C R, Rinaldi M G
机构信息
Department of Pathology and WHO Collaborating Center for Tropical Diseases, University of Texas Medical Branch, Galveston 77555-0609, USA.
出版信息
Antimicrob Agents Chemother. 1997 Aug;41(8):1832-4. doi: 10.1128/AAC.41.8.1832.
Abstract
Voriconazole was compared to amphotericin B, fluconazole, and itraconazole by using an in vitro macrobroth dilution test based upon current National Committee for Clinical Laboratory Standards tentative standards against the dimorphic fungi and several opportunistic molds and yeasts. In all instances, the voriconazole MICs were lower than those of fluconazole. In most instances, the MICs were lower than the recorded MICs of amphotericin B and itraconazole.
摘要
通过使用基于美国国家临床实验室标准委员会针对双相真菌以及几种机会性霉菌和酵母菌的现行暂行标准的体外常量肉汤稀释试验，将伏立康唑与两性霉素B、氟康唑和伊曲康唑进行了比较。在所有情况下，伏立康唑的最低抑菌浓度（MIC）均低于氟康唑。在大多数情况下，其MIC低于两性霉素B和伊曲康唑所记录的MIC。
相似文献
1
In vitro evaluation of voriconazole against some clinically important fungi.伏立康唑对某些临床重要真菌的体外评价。
Antimicrob Agents Chemother. 1997 Aug;41(8):1832-4. doi: 10.1128/AAC.41.8.1832.
2
In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.泊沙康唑、氟康唑、伊曲康唑、伏立康唑和两性霉素B对大量临床重要霉菌和酵母菌的体外活性。
Antimicrob Agents Chemother. 2006 Jun;50(6):2009-15. doi: 10.1128/AAC.00163-06.
3
In vitro activity of voriconazole against selected fungi.
Med Mycol. 1998 Aug;36(4):239-42.
4
In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.新型三唑类药物伏立康唑（UK-109,496）对机会性丝状真菌和双相真菌以及常见和新出现的酵母病原体的体外活性。
J Clin Microbiol. 1998 Jan;36(1):198-202. doi: 10.1128/JCM.36.1.198-202.1998.
5
In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.伏立康唑、伊曲康唑和两性霉素B对机会性念珠菌和暗色真菌的体外杀真菌活性。
J Clin Microbiol. 2001 Mar;39(3):954-8. doi: 10.1128/JCM.39.3.954-958.2001.
6
In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.采用美国国家临床实验室标准化委员会（NCCLS）方法测定伏立康唑及对照药物的体外抗真菌活性：文献综述
Mycopathologia. 2001;150(3):101-15. doi: 10.1023/a:1010954803886.
7
In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.伏立康唑、伊曲康唑和两性霉素B对丝状真菌的体外活性。
J Antimicrob Chemother. 1998 Dec;42(6):741-5. doi: 10.1093/jac/42.6.741.
8
In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin.伏立康唑与伊曲康唑、酮康唑、两性霉素B和灰黄霉素相比，对酵母、霉菌和皮肤癣菌临床分离株的体外评价
Mycoses. 1998 Sep-Oct;41(7-8):309-19. doi: 10.1111/j.1439-0507.1998.tb00344.x.
9
In vitro activity of voriconazole against yeasts, moulds and dermatophytes in comparison with fluconazole, amphotericin B and griseofulvin.伏立康唑与氟康唑、两性霉素B和灰黄霉素相比，对酵母、霉菌和皮肤癣菌的体外活性。
Arzneimittelforschung. 1997 Nov;47(11):1257-63.
10
In vitro antifungal activity of Indian liposomal amphotericin B against clinical isolates of emerging species of yeast and moulds, and its comparison with amphotericin B deoxycholate, voriconazole, itraconazole and fluconazole.印度脂质体两性霉素 B 对新兴酵母和霉菌临床分离株的体外抗真菌活性及其与两性霉素 B 去氧胆酸盐、伏立康唑、伊曲康唑和氟康唑的比较。
Mycoses. 2013 Jan;56(1):39-46. doi: 10.1111/j.1439-0507.2012.02197.x. Epub 2012 Apr 23.
引用本文的文献
1
Development and validation of a colorimetric antifungal susceptibility testing method for the dimorphic fungus Talaromyces marneffei.显色法测定二相性真菌马尔尼菲篮状菌抗真菌药物敏感性的方法的建立和验证。
Med Mycol. 2023 Nov 6;61(11). doi: 10.1093/mmy/myad111.
2
Genomewide Elucidation of Drug Resistance Mechanisms for Systemically Used Antifungal Drugs Amphotericin B, Caspofungin, and Voriconazole in the Budding Yeast.系统使用的抗真菌药物两性霉素 B、卡泊芬净和伏立康唑的耐药机制的全基因组阐明。
Antimicrob Agents Chemother. 2019 Aug 23;63(9). doi: 10.1128/AAC.02268-18. Print 2019 Sep.
3
Scedosporium apiospermum: A Rare Cause of Aggressive Orbital Apex Syndrome.伪阿利什霉：侵袭性眶尖综合征的罕见病因。
Cureus. 2018 Dec 17;10(12):e3743. doi: 10.7759/cureus.3743.
4
Arthroconidia in lung tissue: an unusual histopathological finding in pulmonary coccidioidomycosis.肺组织中的关节孢子：肺球孢子菌病中一种不常见的组织病理学发现。
Hum Pathol. 2018 Jan;71:55-59. doi: 10.1016/j.humpath.2017.07.013. Epub 2017 Aug 1.
5
Identification of New Antifungal Compounds Targeting Thioredoxin Reductase of Paracoccidioides Genus.鉴定针对副球孢子菌属硫氧还蛋白还原酶的新型抗真菌化合物。
PLoS One. 2015 Nov 16;10(11):e0142926. doi: 10.1371/journal.pone.0142926. eCollection 2015.
6
Black Molds and Melanized Yeasts Pathogenic to Humans.对人类致病的黑色霉菌和黑化酵母。
Cold Spring Harb Perspect Med. 2014 Nov 10;5(8):a019570. doi: 10.1101/cshperspect.a019570.
7
Dimorphic fungal osteoarticular infections.双相真菌性骨关节炎感染
Eur J Clin Microbiol Infect Dis. 2014 Dec;33(12):2131-40. doi: 10.1007/s10096-014-2149-0. Epub 2014 Jun 18.
8
Synthesis and antimicrobial evaluation of some novel 1,2,4-triazole and 1,3,4-thiadiazole derivatives.一些新型1,2,4-三唑和1,3,4-噻二唑衍生物的合成与抗菌活性评价
Med Chem Res. 2013 Jul;22(7):3134-3147. doi: 10.1007/s00044-012-0302-9. Epub 2012 Nov 11.
9
Penicillium marneffei presenting as an immune reconstitution inflammatory syndrome (IRIS) in a patient with advanced HIV.马尔尼菲青霉菌在一名晚期艾滋病患者中表现为免疫重建炎症综合征（IRIS）。
BMJ Case Rep. 2013 Jan 28;2013:bcr2012007555. doi: 10.1136/bcr-2012-007555.
10
Microplate alamarBlue assay for Paracoccidioides susceptibility testing.微板 alamarBlue 法用于检测泊拉卡氏菌的敏感性。
J Clin Microbiol. 2013 Apr;51(4):1250-2. doi: 10.1128/JCM.02914-12. Epub 2013 Jan 23.
本文引用的文献
1
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.抗真菌药敏试验解释性断点的制定：氟康唑、伊曲康唑和念珠菌感染的体外-体内相关性数据的概念框架与分析。美国国家临床实验室标准委员会抗真菌药敏试验小组委员会
Clin Infect Dis. 1997 Feb;24(2):235-47. doi: 10.1093/clinids/24.2.235.
2
In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.新型三唑类抗真菌药物伏立康唑（UK-109,496）对新出现的及较少见霉菌病原体活性的体外研究。
Antimicrob Agents Chemother. 1997 Apr;41(4):841-3. doi: 10.1128/AAC.41.4.841.
3
Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.伏立康唑（UK-109,496）对曲霉属临床分离株的活性及其在侵袭性肺曲霉病实验模型中的有效性。
Antimicrob Agents Chemother. 1997 Mar;41(3):696-8. doi: 10.1128/AAC.41.3.696.
4
Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs.伏立康唑（UK-109,496）与伊曲康唑预防和治疗豚鼠烟曲霉性心内膜炎的比较。
Antimicrob Agents Chemother. 1997 Jan;41(1):13-6. doi: 10.1128/AAC.41.1.13.
5
In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species.两种三唑类抗真菌剂（伏立康唑[UK-109,496]和氟康唑）对念珠菌属的体外研究。
Antimicrob Agents Chemother. 1996 Aug;40(8):1948-9. doi: 10.1128/AAC.40.8.1948.
6
Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.新型唑类抗真菌药UK-109496在侵袭性曲霉病实验模型中的疗效
Antimicrob Agents Chemother. 1996 Jan;40(1):86-91. doi: 10.1128/AAC.40.1.86.
Zotero 插件